Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 30
Maximum Age: 62
View:
• residents in Southern China
• 30-62 years old
• male
• a first-degree relative of at least one nasopharyngeal carcinoma patient
• no medical record of nasopharyngeal carcinoma
• Eastern Cooperative Oncology Group score of 0-2
• be able to comprehend, sign, and date the written informed consent document to participate in the study
Locations
Other Locations
China
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
RECRUITING
Guangzhou
Contact Information
Primary
Ming-Yuan Chen, MD, PhD
chmingy@mail.sysu.edu.cn
86-20-8734-3361
Backup
Si-Yuan Chen, MD
chensy@sysucc.org.cn
86-18711150216
Time Frame
Start Date: 2022-07-10
Estimated Completion Date: 2030-07-01
Participants
Target number of participants: 11625
Treatments
High risk population of nasopharyngeal carcinoma
first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
Related Therapeutic Areas
Sponsors
Collaborators: Hunan Cancer Hospital, Changsha Central Hospital, Yuebei People's Hospital, Wuzhou Red Cross Hospital, The Third Affiliated Hospital of Nanchang University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Xiangya Hospital of Central South University
Leads: Sun Yat-sen University